199 related articles for article (PubMed ID: 28124380)
1. Methylated free-circulating HPP1 DNA is an early response marker in patients with metastatic colorectal cancer.
Herbst A; Vdovin N; Gacesa S; Ofner A; Philipp A; Nagel D; Holdt LM; Op den Winkel M; Heinemann V; Stieber P; Graeven U; Reinacher-Schick A; Arnold D; Ricard I; Mansmann U; Hegewisch-Becker S; Kolligs FT
Int J Cancer; 2017 May; 140(9):2134-2144. PubMed ID: 28124380
[TBL] [Abstract][Full Text] [Related]
2. Circulating cell-free methylated DNA and lactate dehydrogenase release in colorectal cancer.
Philipp AB; Nagel D; Stieber P; Lamerz R; Thalhammer I; Herbst A; Kolligs FT
BMC Cancer; 2014 Apr; 14():245. PubMed ID: 24708595
[TBL] [Abstract][Full Text] [Related]
3. Prognostic role of methylated free circulating DNA in colorectal cancer.
Philipp AB; Stieber P; Nagel D; Neumann J; Spelsberg F; Jung A; Lamerz R; Herbst A; Kolligs FT
Int J Cancer; 2012 Nov; 131(10):2308-19. PubMed ID: 22362391
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and clinicopathological significance of circulating tumor cells detected by RT-PCR in non-metastatic colorectal cancer: a meta-analysis and systematic review.
Yang C; Zou K; Zheng L; Xiong B
BMC Cancer; 2017 Nov; 17(1):725. PubMed ID: 29115932
[TBL] [Abstract][Full Text] [Related]
5. Aberrant methylation of the HPP1 gene in ulcerative colitis-associated colorectal carcinoma.
Sato F; Shibata D; Harpaz N; Xu Y; Yin J; Mori Y; Wang S; Olaru A; Deacu E; Selaru FM; Kimos MC; Hytiroglou P; Young J; Leggett B; Gazdar AF; Toyooka S; Abraham JM; Meltzer SJ
Cancer Res; 2002 Dec; 62(23):6820-2. PubMed ID: 12460892
[TBL] [Abstract][Full Text] [Related]
6. A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer.
Barbazán J; Muinelo-Romay L; Vieito M; Candamio S; Díaz-López A; Cano A; Gómez-Tato A; Casares de Cal Mde L; Abal M; López-López R
Int J Cancer; 2014 Dec; 135(11):2633-43. PubMed ID: 24752533
[TBL] [Abstract][Full Text] [Related]
7. Methylation of serum DNA is an independent prognostic marker in colorectal cancer.
Wallner M; Herbst A; Behrens A; Crispin A; Stieber P; Göke B; Lamerz R; Kolligs FT
Clin Cancer Res; 2006 Dec; 12(24):7347-52. PubMed ID: 17189406
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers for the early detection of relapses in metastatic colorectal cancers.
Chereches G; Barbos O; Buiga R; Balacescu O; Iancu D; Todor N; Balacescu L; Miron N; Bejinariu N; Ciuleanu TE
J BUON; 2017; 22(3):658-666. PubMed ID: 28730771
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk.
Schulmann K; Sterian A; Berki A; Yin J; Sato F; Xu Y; Olaru A; Wang S; Mori Y; Deacu E; Hamilton J; Kan T; Krasna MJ; Beer DG; Pepe MS; Abraham JM; Feng Z; Schmiegel W; Greenwald BD; Meltzer SJ
Oncogene; 2005 Jun; 24(25):4138-48. PubMed ID: 15824739
[TBL] [Abstract][Full Text] [Related]
10. HPP1: a transmembrane protein-encoding gene commonly methylated in colorectal polyps and cancers.
Young J; Biden KG; Simms LA; Huggard P; Karamatic R; Eyre HJ; Sutherland GR; Herath N; Barker M; Anderson GJ; Fitzpatrick DR; Ramm GA; Jass JR; Leggett BA
Proc Natl Acad Sci U S A; 2001 Jan; 98(1):265-70. PubMed ID: 11120884
[TBL] [Abstract][Full Text] [Related]
11. Methylation of helicase-like transcription factor in serum of patients with colorectal cancer is an independent predictor of disease recurrence.
Herbst A; Wallner M; Rahmig K; Stieber P; Crispin A; Lamerz R; Kolligs FT
Eur J Gastroenterol Hepatol; 2009 May; 21(5):565-9. PubMed ID: 19282772
[TBL] [Abstract][Full Text] [Related]
12. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis.
Lecomte T; Berger A; Zinzindohoué F; Micard S; Landi B; Blons H; Beaune P; Cugnenc PH; Laurent-Puig P
Int J Cancer; 2002 Aug; 100(5):542-8. PubMed ID: 12124803
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab.
Sastre J; Vidaurreta M; Gómez A; Rivera F; Massutí B; López MR; Abad A; Gallen M; Benavides M; Aranda E; Rubio ED;
Clin Colorectal Cancer; 2013 Dec; 12(4):280-6. PubMed ID: 24012456
[TBL] [Abstract][Full Text] [Related]
14. Hypermethylation of the TPEF/HPP1 gene in primary and metastatic colorectal cancers.
Ebert MP; Mooney SH; Tonnes-Priddy L; Lograsso J; Hoffmann J; Chen J; Röcken C; Schulz HU; Malfertheiner P; Lofton-Day C
Neoplasia; 2005 Aug; 7(8):771-8. PubMed ID: 16207479
[TBL] [Abstract][Full Text] [Related]
15. Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer.
Spindler KL; Pallisgaard N; Andersen RF; Brandslund I; Jakobsen A
PLoS One; 2015; 10(4):e0108247. PubMed ID: 25875772
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy.
Spindler KL; Pallisgaard N; Appelt AL; Andersen RF; Schou JV; Nielsen D; Pfeiffer P; Yilmaz M; Johansen JS; Hoegdall EV; Jakobsen A; Jensen BV
Eur J Cancer; 2015 Nov; 51(17):2678-85. PubMed ID: 26508156
[TBL] [Abstract][Full Text] [Related]
17. Methodological, biological and clinical aspects of circulating free DNA in metastatic colorectal cancer.
Spindler KG
Acta Oncol; 2017 Jan; 56(1):7-16. PubMed ID: 28010185
[TBL] [Abstract][Full Text] [Related]
18. Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients.
Ronzoni M; Manzoni M; Mariucci S; Loupakis F; Brugnatelli S; Bencardino K; Rovati B; Tinelli C; Falcone A; Villa E; Danova M
Ann Oncol; 2010 Dec; 21(12):2382-2389. PubMed ID: 20497963
[TBL] [Abstract][Full Text] [Related]
19. Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer.
Mahon KL; Qu W; Devaney J; Paul C; Castillo L; Wykes RJ; Chatfield MD; Boyer MJ; Stockler MR; Marx G; Gurney H; Mallesara G; Molloy PL; Horvath LG; Clark SJ;
Br J Cancer; 2014 Oct; 111(9):1802-9. PubMed ID: 25144624
[TBL] [Abstract][Full Text] [Related]
20. LINE-1 hypomethylation status of circulating cell-free DNA in plasma as a biomarker for colorectal cancer.
Nagai Y; Sunami E; Yamamoto Y; Hata K; Okada S; Murono K; Yasuda K; Otani K; Nishikawa T; Tanaka T; Kiyomatsu T; Kawai K; Nozawa H; Ishihara S; Hoon DS; Watanabe T
Oncotarget; 2017 Feb; 8(7):11906-11916. PubMed ID: 28060757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
